MetaCap

Dermata Therapeutics (DRMA) vs Gelteq (GELS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

Gelteq is the larger company by market cap ($5.9 million vs $5.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Head-to-head

DRMA versus GELS key metrics
MetricDRMAGELS
Share price$1.07$0.5488
Market cap$5.30M$5.88M
1-day change-4.46%-1.98%
EPS (TTM)$-4.39$-0.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$4.84$2.01
52-week low$0.951$0.387
Distance from 52-week high-77.89%-72.70%
Average volume708.18K2.86M
Shares outstanding4.96M10.71M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

DRMA vs GELS FAQ

Which is bigger, Dermata Therapeutics or Gelteq?

Gelteq (GELS) is larger, with a market capitalization of $5.88M compared with $5.30M for Dermata Therapeutics (DRMA).

Are Dermata Therapeutics and Gelteq in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons